Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Core Points - Aptorum Group Limited has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares closed at least $1.00 for 10 consecutive business days prior to the October 14, 2025 deadline [1][2][3] - The closing bid price was maintained at $1.00 or greater from July 16, 2025 to July 30, 2025, leading to the closure of the compliance matter by Nasdaq [2][3] - Aptorum Group announced an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary upon completion of the transaction [4] Company Overview - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [5] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology based on microRNA signatures [6]